|
Mechanismadrenergic receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date08 Nov 1967 |
100 Clinical Results associated with G2B Pharma, Inc.
0 Patents (Medical) associated with G2B Pharma, Inc.
100 Deals associated with G2B Pharma, Inc.
100 Translational Medicine associated with G2B Pharma, Inc.